Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
-
Behzad Poopak
,
Saghar Rabieipoor
,
Nazila Safari
,
Emadedin Naraghi
,
Fatemeh Sheikhsofla
,
Gelareh Khosravipoor
Abstract
Background: Although catalytic properties of different genetic polymorphisms of VKORC1 and CYP2C9 products have been identified, there is limited study available regarding warfarin dose requirement in Iranian patient population. This study investigates the impact of these polymorphisms on 115 patients, referred to Payvand Clinical and Specialty Laboratory for determining the appropriate dose of warfarin. Results of the study may be applicable to individuals who are under warfarin therapy to avoid warfarin resistance or intolerance.
Subjects and Methods: PT-INR test was utilized as a screening method. Genotyping were performed for VKORC1 and CYP2C9 using PCR method. Statistical analyses including unpaired t-test or ANOVA and regression were done using SPSS.
Results: VKORC1 GA was the most common genotype of VKORC1 allele among the study samples, with a rate of 57.4%. In CYP2C9 variant, 20% and 14.8% of subjects carried CYP2C9*1/*2 and CYP2C9*1/*3 genotyping, respectively. By contrast, the WT *1/*1 genotype was more abundant and dominant. The high frequency of VKORC1 (_1639) GA genotype (57.4%), was significant versus for the rest of the cohort (42.6%). In addition, a significant relationship was found between CYP2C9*1 and drug dose (P>0.021).
Conclusion: In this study, samples were characterized by higher frequencies of CYP2C9*1 and VKORC1 G/A, determined as higher warfarin taking doses. The results showed a significant relationship of the VCORC1 and CYP2C9 polymorphisms with warfarin sensitivity and severe side effects. Estimating right doses of warfarin to prescribe can help to reduce the risk of over- or under-anticoagulation and subsequently, the risk of thromboembolism or bleeding.
Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-Rationale and perspectives. Thromb Res. 2007; 120(1):1-10.
Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics . 2011; 12(1): 15-25.
Samiee SM, Mohammadi Yeganeh S, Paryan M, et al. Polymorphism Detection of VKORC1 and CYP2C9 genes for warfarin dose adjustment by Real-Time PCR. Thrita. 2014; 3(1): e14033.
Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics. 2005; 5(4): 262-70.
Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008; 358(10):999-1008.
Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008; 84 (1): 83-9.
Moreau C, Pautas E, Gouin-Thibault I, et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost. 2011; 9(4):711-8.
HCM Yu, Chan TYK, Critchley J, et al. Factors determining the maintenance dose of warfarin in Chinese patients. Q J M. 1996; 89(2):127-35.
Heather P, Whitley W. Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag. 2007; 3(3):499-504.
Lee V, You J, Lee K, et al. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis. 2005; 20(1): 33-38.
Johnson M, Richard C, Bogdan R, et al. Warfarin dosing in a patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA genotypes. Case Reports in Genetics. 2014. 2014:1-4.
Jorge-Nebert LF, Jiang Z, Chakraborty R, et al. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat. 2010; 31(1):27-40.
Kaminsky LS, Zhang ZY. Human P450 meta bolism of warfarin. Pharmacology and Therapeutics. 1997; 73(1): 67-74.
Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) is predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther; 2009. 87(1):57-64.
Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106(7): 2329-33.
Greaves M. Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?. PLoS Med. 2005. 2(10): e342.
Kianmehr Z, Ghadam P, Sadrai S, et al. VKORC1 gene analysis of some Iranian sensitive patients to warfarin. Pak J Biol Sci. 2010; 13: 96-910.
Gage B, Eby C, Milligan P, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004; 91(1):87-94.
Ghadam P, Sadeghian F, Sharifian R, et al. VKORC1 gene analysis in an Iranian warfarin resistant patient. Journal of Biological Sciences. 2008; 8: 691-2.
Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest. 2001; 119 (Suppl.1): 108-121.
Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol. 2012; 73(3): 340-7.
Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10(2):139-50.
| Files | ||
| Issue | Vol 9, No 4 (2015) | |
| Section | Articles | |
| Keywords | ||
| CYP2C9 and VKORC1 polymorphisms Polymerase Change Reaction Warfarin dose requirements | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
